저자의 연구 키워드

저자의 연구 키워드

#가중평균자본비용

#감사인 지정

#검토의견

#경영자의 재량권

#과대평가

#규제강화조치

#글로벌 제약사 회계처리

#기술성장상장

#기술성장상장제도

#기업신용등급

#내부회계관리제도

#무형자산

#미청구공사

#보수주의 회계처리

#복합금융상품

#부채조달비용

#성과평가지표

#성장성 추천상장

#셀리버리

#수익비용대응

#수주산업 회계투명성 제고방안

#시장의 인식

#신규상장

#신용보증재단

#실물활동을 통한 이익조정

#연구개발비

#외감법

#우회상장

#유가증권상장기업

#의무보호예수

#이익유연화

#이익의 질

#자기자본비용

#자본화

#재량적 발생액

#전환사채

#제3자 지정 콜옵션

#제약·바이오기업

#주기적 지정

#중요성 판단

#지적사유

#직권지정

#최대주주

#추정 재무제표

#추정재무제표

#코스닥상장기업

#콜옵션

#콜옵션 전환사채

#크라우드펀딩

#타인자본비용

#판텍스

#프로스포츠

#피셔의 z값

#회계이익의 불투명성

#Accounting conservatism

#Accounting Opacity

#Accounting receivable

#Accounting Transparency Improvement Plan

#AHP

#Audit review

#backdoor listing

#backdoor listing firms

#Call option convertible bonds

#Call options

#Cellivery

#Completion rates

#Compulsory Separate Safekeeping

#Contract industry

#Convertible bonds

#Cost of capital

#cost of debt

#Credit Guarantee Foundation

#Credit rating

#crowdfunding

#Dentium

#Determinants.

#Dio

#direct designation

#Discretionary accruals

#Due from customers for construct work accumulated impairment losses

#Earnings quality

#Entertainment expenses.

#Factoring

#Fantex

#Financial analysis

#Fisher’s r－to－z transformation

#Global pharmaceutical company accounting

#IAMS

#Implant industry

#Income smoothing

#initial public offering

#Intangible assets

#internal accounting control system

#internal accounting management system

#Internal Accounting Management Systems

#Internal Control over Financial Reporting Officer

#IPO

#KOSDAQ Listed firms

#KSE Listed firms

#Largest Shareholder

#Listing eligibility review

#manager’s discretion

#mandatory auditor designation

#Moneual

#Osstem

#Overestimation

#Performance Evaluation Indices

#periodic designation

#Perquisites Consumptions

#Pharmaceutical and bio companies

#Possibility of listing

#pro forma financial statements

#professional player

#Pro-Forma Financial Statements

#real activity earnings management

#reason

#Recommendation on Growth Potential Listing

#regulatory system of backdoor listing

#Research and development expenses

#Revenue recognition

#revenue－expense matching

#reverse takeover

#review opinion

#Review paper

#Sales return

#Significance Judgement

#Technology Growth Listing

#Technology-Growth Company

#The External Audit Law

#Third-party designated call options

#Unbilled Receivable

#weighted average cost of capital